GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bayer AG (XTER:BAYN) » Definitions » Debt-to-Revenue

Bayer AG (XTER:BAYN) Debt-to-Revenue : 0.90 (As of Dec. 2023)


View and export this data going back to 1953. Start your Free Trial

What is Bayer AG Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Bayer AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €4,704 Mil. Bayer AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €38,170 Mil. Bayer AG's annualized Revenue for the quarter that ended in Dec. 2023 was €47,448 Mil. Bayer AG's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.90.


Bayer AG Debt-to-Revenue Historical Data

The historical data trend for Bayer AG's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bayer AG Debt-to-Revenue Chart

Bayer AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 1.00 0.90 0.81 0.90

Bayer AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 - - - 0.90

Competitive Comparison of Bayer AG's Debt-to-Revenue

For the Drug Manufacturers - General subindustry, Bayer AG's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bayer AG's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bayer AG's Debt-to-Revenue falls into.



Bayer AG Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Bayer AG's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4704 + 38170) / 47637
=0.90

Bayer AG's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4704 + 38170) / 47448
=0.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Bayer AG Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bayer AG's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Bayer AG (XTER:BAYN) Business Description

Address
Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.

Bayer AG (XTER:BAYN) Headlines